These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15142121)

  • 1. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
    Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
    Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
    Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Br J Haematol; 2002 Jan; 116(1):162-5. PubMed ID: 11841411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
    Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
    Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
    Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
    Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
    Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W; Kondo M; Tokoro A
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
    Jørgensen HG; Copland M; Allan EK; Jiang X; Eaves A; Eaves C; Holyoake TL
    Clin Cancer Res; 2006 Jan; 12(2):626-33. PubMed ID: 16428509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
    Mor-Tzuntz R; Uziel O; Shpilberg O; Lahav J; Raanani P; Bakhanashvili M; Rabizadeh E; Zimra Y; Lahav M; Granot G
    Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.